title: Update on duloxetine for the management of stress urinary incontinence.
abstract: Duloxetine is a relatively balanced serotonin and noradrenaline reuptake inhibitor (SNRI), which is the first drug with widely proven efficacy to have been licensed for the medical treatment of women with stress urinary incontinence (SUI). Despite favorable results from randomized controlled trials, surgical management continues to be the mainstay of treatment for SUI. In this review we explore the pharmacology of duloxetine in the nervous system and lower urinary tract, and the evidence for its use in the management of women with urinary incontinence.
authors.affiliation: Department of Obstetrics and Gynaecology, Medway Maritime Hospital, Gillingham, Kent, UK.
authors.forename: Maya
authors.initials: M
authors.lastname: Basu
authors.forename: Jonathan R A
authors.initials: JR
authors.lastname: Duckett
mesh_terms: D003863:Depression / Q000188:drug therapy; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D009420:Nervous System / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use; D006113:United Kingdom; D053201:Urinary Bladder, Overactive / Q000188:drug therapy; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*; D014551:Urinary Tract / Q000187:drug effects
chemical_list: D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes